GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (FRA:41O) » Definitions » Institutional Ownership

Outlook Therapeutics (FRA:41O) Institutional Ownership : 5.66% (As of Jun. 01, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Outlook Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Outlook Therapeutics's institutional ownership is 5.66%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Outlook Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Outlook Therapeutics's Float Percentage Of Total Shares Outstanding is 83.48%.


Outlook Therapeutics Institutional Ownership Historical Data

The historical data trend for Outlook Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics Institutional Ownership Chart

Outlook Therapeutics Historical Data

The historical data trend for Outlook Therapeutics can be seen below:

2023-06-30 2023-07-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 11.14 11.14 10.83 9.58 9.86 10.00 9.94 9.93 6.10 5.66

Outlook Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Outlook Therapeutics (FRA:41O) Business Description

Traded in Other Exchanges
Address
485 Route 1 South Building F, Suite 320, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Outlook Therapeutics (FRA:41O) Headlines

No Headlines